JPWO2019152742A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019152742A5 JPWO2019152742A5 JP2020541882A JP2020541882A JPWO2019152742A5 JP WO2019152742 A5 JPWO2019152742 A5 JP WO2019152742A5 JP 2020541882 A JP2020541882 A JP 2020541882A JP 2020541882 A JP2020541882 A JP 2020541882A JP WO2019152742 A5 JPWO2019152742 A5 JP WO2019152742A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- specific car
- domain
- amino acid
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 68
- 210000002865 immune cell Anatomy 0.000 claims 45
- 210000004027 cell Anatomy 0.000 claims 39
- 125000003275 alpha amino acid group Chemical group 0.000 claims 36
- 238000000034 method Methods 0.000 claims 24
- 108091033319 polynucleotide Proteins 0.000 claims 15
- 102000040430 polynucleotide Human genes 0.000 claims 15
- 239000002157 polynucleotide Substances 0.000 claims 15
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 108020001756 ligand binding domains Proteins 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 230000004068 intracellular signaling Effects 0.000 claims 9
- 208000032612 Glial tumor Diseases 0.000 claims 8
- 206010018338 Glioma Diseases 0.000 claims 8
- 208000017604 Hodgkin disease Diseases 0.000 claims 8
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 8
- 102000009438 IgE Receptors Human genes 0.000 claims 8
- 108010073816 IgE Receptors Proteins 0.000 claims 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 8
- 230000003211 malignant effect Effects 0.000 claims 8
- 201000000050 myeloid neoplasm Diseases 0.000 claims 8
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 6
- 108010065524 CD52 Antigen Proteins 0.000 claims 6
- 230000031146 intracellular signal transduction Effects 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 4
- 206010010144 Completed suicide Diseases 0.000 claims 4
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims 4
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 4
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 238000003556 assay Methods 0.000 claims 4
- 201000000053 blastoma Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000009089 cytolysis Effects 0.000 claims 4
- 201000008184 embryoma Diseases 0.000 claims 4
- 201000003444 follicular lymphoma Diseases 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 208000030173 low grade glioma Diseases 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 2
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- -1 or TCRα Proteins 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 230000005751 tumor progression Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Claims (99)
a)前記細胞群は、幹細胞メモリー細胞およびセントラルメモリー細胞の20%、30%または40%よりも高い割合を構成し、および/または
b)前記細胞群は、実施例4に開示されるアッセイを使用して測定されるときに、6日目で、再帰的CD70発現細胞に対し、10%、20%、30%または40%よりも高いCD70発現細胞の溶解割合を達成する、細胞群。 The group of cells according to any one of claims 27 to 38.
a) The cell population constitutes a proportion greater than 20%, 30% or 40% of stem cell memory cells and central memory cells, and / or b) the cell population comprises the assay disclosed in Example 4. A group of cells that achieves a lysis rate of CD70-expressing cells greater than 10%, 20%, 30% or 40% relative to recursive CD70-expressing cells when measured using.
a)免疫細胞を提供すること、および
b)請求項1~23のいずれか1項に記載の少なくとも一つのCD70特異的CARを、前記細胞の表面に発現させること、を含む、方法。 A method of manipulating immune cells
A method comprising a) providing immune cells and b) expressing at least one CD70-specific CAR according to any one of claims 1 to 23 on the surface of said cells.
b)前記細胞に、前記CD70特異的CARをコードする少なくとも一つのポリヌクレオチドを導入すること、および
c)前記細胞内で前記ポリヌクレオチドを発現させること、を含む、請求項41に記載の免疫細胞を操作する方法。 a) Providing immune cells,
The immune cell according to claim 41, comprising (b) introducing at least one polynucleotide encoding the CD70-specific CAR into the cell, and c) expressing the polynucleotide within the cell. How to operate.
b)前記細胞に、前記CD70特異的CARをコードする少なくとも一つのポリヌクレオチドを導入すること、および
c)CD70に特異的ではない少なくとも一つの他のCARを導入すること、を含む、請求項41に記載の免疫細胞を操作する方法。 a) Providing immune cells,
41. The cell comprises the introduction of at least one polynucleotide encoding the CD70-specific CAR, and c) the introduction of at least one other CAR that is not CD70-specific. The method of manipulating immune cells according to.
a)請求項1~23のいずれか1項に記載のCD70特異的CARを、表面に発現する免疫細胞を提供すること、および
b)前記免疫細胞を前記患者に投与すること、を含む、方法。 It ’s a way to treat the subject in need,
A method comprising a) providing an immune cell expressing the CD70-specific CAR according to any one of claims 1 to 23 on the surface, and b) administering the immune cell to the patient. ..
a)前記VH領域は、配列番号18と少なくとも95%、96%、97%、98%、99%、または100%共通するアミノ酸配列を含有し、前記VL領域は、配列番号17と少なくとも95%、96%、97%、98%、99%、または100%共通するアミノ酸配列を含有し;または
b)前記VH領域は、配列番号34と少なくとも95%、96%、97%、98%、99%、または100%共通するアミノ酸配列を含有し、前記VL領域は、配列番号33と少なくとも95%、96%、97%、98%、99%、または100%共通するアミノ酸配列を含有する、CD70特異的CAR。 A Cruster of Differation 70-specific chimeric antigen receptor (CD70-specific CAR) comprising an extracellular ligand-binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the extracellular domain is a heavy chain variable (VH). ) And a single chain Fv fragment (scFv) that binds to the extracellular domain of CD70 with a light chain variable (VL) region.
a) The VH region contains an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% common to SEQ ID NO: 18, and the VL region is at least 95% with SEQ ID NO: 17. , 96%, 97%, 98%, 99%, or 100% of the amino acid sequence in common; or b) said VH region is at least 95%, 96%, 97%, 98%, 99 with SEQ ID NO: 34. The VL region contains an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% common to SEQ ID NO: 33, CD70. Specific CAR.
a)配列番号297と少なくとも95%、96%、97%、98%、99%、または100%共通し、および配列番号298と少なくとも95%、96%、97%、98%、99%、または100%共通する核酸配列を含有するか、または
b)配列番号307と少なくとも95%、96%、97%、98%、99%、または100%共通し、および配列番号308と少なくとも95%、96%、97%、98%、99%、または100%共通する核酸配列を含有する、ポリヌクレオチド。 A polynucleotide encoding a CD70-specific CAR, wherein the polynucleotide is.
a) At least 95%, 96%, 97%, 98%, 99%, or 100% in common with SEQ ID NO: 297, and at least 95%, 96%, 97%, 98%, 99%, or with SEQ ID NO: 298. Contains a nucleic acid sequence that is 100% common, or b) at least 95%, 96%, 97%, 98%, 99%, or 100% common with SEQ ID NO: 307, and at least 95%, 96 with SEQ ID NO: 308. A polynucleotide containing a nucleic acid sequence that is%, 97%, 98%, 99%, or 100% common.
a)配列番号49~51、55~57、61~63、67~69、73~75、79~81、85~87、91~93、97~99、103~105、109~111、115~117、121~123、127~129、133~135、139~141、145~147、151~153、157~159、163~165、169~171、175~177、181~183、187~189、382~384、388~390、394~396、400~402、406~408、412~414、418~420、424~426、430~432、436~438、442~444、448~450、454~456、460~462、466~468、472~474、478~480、484~486、490~492、496~498、502~504、および508~510からなる群から選択されるアミノ酸配列を含む可変重鎖CDR1、
b)配列番号52、53、58、59、64、65、70、71、76、77、82、83、88、89、94、95、100、101、106、107、112、113、118、119、124、125、130、131、136、137、142、143、148、149、154、155、160、161、166、167、172、173、178、179、184、185、190、191、385、386、391、392、397、398、403、404、409、410、415、416、421、422、427、428、433、434、439、440、445、446、451、452、457、458、463、464、469、470、475、476、481、482、487、488、493、494、499、500、505、506、511、および512からなる群から選択されるアミノ酸配列を含む可変重鎖CDR2、
c)配列番号54、60、66、72、78、84、90、96、102、108、114、120、126、132、138、144、150、156、162、168、174、180、186、192、387、393、399、405、411、417、423、429、435、441、447、453、459、465、471、477、483、489、495、501、507、および513からなる群から選択されるアミノ酸配列を含む可変重鎖CDR3、
d)配列番号193、196、199、202、205、208、211、214、217、220、223、226、229、232、235、238、241、244、247、250、253、256、259、262、514、517、520、523、526、529、532、535、538、541、544、547、550、553、556、559、562、565、568、571、574、および577からなる群から選択されるアミノ酸配列を含む可変軽鎖CDR1、
e)配列番号194、197、200、203、206、209、212、215、218、221、224、227、230、233、236、239、242、245、248、251、254、257、260、263、515、518、521、524、527、530、533、536、539、542、545、548、551、554、557、560、563、566、569、572、575、および578からなる群から選択されるアミノ酸配列を含む可変軽鎖CDR2、ならびに
f)配列番号195、198、201、204、207、210、213、216、219、222、225、228、231、234、237、240、243、246、249、252、255、258、261、264、516、519、522、525、528、531、534、537、540、543、546、549、552、555、558、561、564、567、570、573、576、および579からなる群から選択されるアミノ酸配列を含む可変軽鎖CDR3、のうちの少なくとも一つを含む、キメラ抗原受容体(CAR)。 A chimeric antigen receptor (CAR) containing an antigen-binding molecule that specifically binds to CD70, said antigen-binding molecule.
a) SEQ ID NOs: 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, 115- 117, 121-123, 127-129, 133-135, 139-141, 145-147, 151-153, 157-159, 163-165, 169-171, 175-177, 181-183, 187-189, 382-384, 388-390, 394-396, 400-402, 406-408, 421-414, 418-420, 424-426, 430-432, 436-438, 442-444, 448-450, 454- Variables comprising amino acid sequences selected from the group consisting of 456, 460 to 462, 466 to 468, 472 to 474, 478 to 480, 484 to 486, 490 to 492, 494 to 498, 502 to 504, and 508 to 510. Heavy chain CDR1,
b) SEQ ID NOs: 52, 53, 58, 59, 64, 65, 70, 71, 76, 77, 82, 83, 88, 89, 94, 95, 100, 101, 106, 107, 112, 113, 118, 119, 124, 125, 130, 131, 136, 137, 142, 143, 148, 149, 154, 155, 160, 161, 166, 167, 172, 173, 178, 179, 184, 185, 190, 191. 385, 386, 391, 392, 397, 398, 403, 404, 409, 410, 415, 416, 421, 422, 427, 428, 433, 434, 439, 440, 445, 446, 451, 452, 457, Variable containing amino acid sequences selected from the group consisting of 458, 463, 464, 469, 470, 475, 476, 481, 482, 487, 488, 493, 494, 499, 500, 505, 506, 511, and 512. Heavy chain CDR2,
c) SEQ ID NO: 54, 60, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132, 138, 144, 150, 156, 162, 168, 174, 180, 186, From the group consisting of 192, 387, 393, 399, 405, 411, 417, 423, 249, 435, 441, 447, 453, 459, 465, 471, 477, 483, 489, 495, 501, 507, and 513. Variable heavy chain CDR3 containing the selected amino acid sequence,
d) SEQ ID NO: 193, 196, 199, 202, 205, 208, 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241 and 244, 247, 250, 253, 256, 259, From the group consisting of 262, 514, 517, 520, 523, 526, 259, 532, 535, 538, 541, 544, 547, 550, 555, 556, 559, 562, 565, 568, 571, 574, and 575. Variable light chain CDR1 containing the selected amino acid sequence,
e) SEQ ID NO: 194, 197, 200, 203, 206, 209, 212, 215, 218, 221, 224, 227, 230, 233, 236, 239, 242, 245, 248, 251, 254, 257, 260, From the group consisting of 263, 515, 518, 521, 524, 527, 530, 533, 536, 359, 542, 545, 548, 551, 554, 557, 560, 563, 566, 569, 572, 575, and 578. Variable light chain CDR2 containing the amino acid sequence of choice, as well as f) SEQ ID NOs: 195, 198, 201, 204, 207, 210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 240, 243. , 246, 249, 252, 255, 258, 261, 264, 516, 589, 522, 525, 528, 513, 534, 537, 540, 543, 546, 549, 552, 555, 558, 561, 564, 567. A chimeric antigen receptor (CAR) comprising at least one of a variable light chain CDR3 comprising an amino acid sequence selected from the group consisting of 570, 573, 576, and 579.
a)それぞれ、配列番号
i)49~51、52~53、54;
ii)55~57、58~59、60;
iii)61~63、64~65、66;
iv)67~69、70~71、72;
v)73~75、76~77、78;
vi)79~81、82~83、84;
vii)85~87、88~89、90;
viii)91~93、94~95、96;
ix)97~99、100~101、102;
x)103~105、106~107、108;
xi)109~111、112~113、114;
xii)115~117、118~119、120;
xiii)121~123、124~125、126;
xiv)127~129、130~131、132;
xv)133~135、136~137、138;
xvi)139~141、142~143、144;
xvii)145~147、148~149、150;
xviii)151~153、154~155、156;
xix)157~159、160~161、162;
xx)163~165、166~167、168;
xxi)169~171、172~173、174;
xxii)175~177、178~179、180;
xxiii)181~183、184~185、186;
xxiv)187~189、190~191、192;
xxv)382~384、385~386、387;
xxvi)388~390、391~392、393;
xxvii)394~396、397~398、399;
xxviii)400~402、403~404、405;
xxix)406~408、409~410、411;
xxx)412~414、415~416、417;
xxxi)418~420、421~422、423;
xxxii)424~426、427~428、429;
xxxiii)430~432、433~434、435;
xxxiv)436~438、439~440、441;
xxxv)442~444、445~446、447;
xxxvi)448~450、451~452、453;
xxxvii)454~456、457~458、459;
xxxviii)460~462、463~464、465;
xxxix)466~468、469~470、471;
xl)472~474、475~476、477;
xli)478~480、481~482、483;
xlii)484~486、487~488、489;
xliii)490~492、493~494、495;
xliv)496~498、499~500、501;
xlv)502~504、505~506、507;または
xlvi)508~510、511~512、513、のうちの一つから選択されるCDRH1、CDRH2およびCDRH3のアミノ酸配列を含む可変重鎖ドメイン;および
b)それぞれ、配列番号
i)193、194、195;
ii)196、197、198;
iii)199、200、201;
iv)202、203、204;
v)205、206、207;
vi)208、209、210;
vii)211、212、213;
viii)214、215、216;
ix)217、218、219;
x)220、221、222;
xi)223、224、225;
xii)226、227、228;
xiii)229、230、231;
xiv)232、233、234;
xv)235、236、237;
xvi)238、239、240;
xvii)241、242、243;
xviii)244、245、246;
xix)247、248、249;
xx)250、251、252;
xxi)253、254、255;
xxii)256、257、258;
xxiii)259、260、261;
xxiv)262、263、264;
xxv)514、515、516;
xxvi)517、518、519;
xxvii)520、521、522;
xxviii)523、524、525;
xxix)526、527、528;
xxx)529、530、531;
xxxi)532、533、534;
xxxii)535、536、537;
xxxiii)538、539、540;
xxxiv)541、542、543;
xxxv)544、545、546;
xxxvi)547、548、549;
xxxvii)550、551、552;
xxxviii)553、554、555;
xxxix)556、557、558;
xl)559、560、561;
xli)562、563、564;
xlii)565、566、567;
xliii)568、569、570;
xliv)571、572、573;
xlv)574、575、576;および
xlvi)577、578、579、のうちの一つから選択されるCDRL1、CDRL2およびCDRL3のアミノ酸配列を含む可変軽鎖ドメイン、を含む、請求項56に記載のCD70特異的CAR。 The antigen-binding molecule
a) SEQ ID NO: i) 49-51, 52-53, 54;
ii) 55-57, 58-59, 60;
iii) 61-63, 64-65, 66;
iv) 67-69, 70-71, 72;
v) 73-75, 76-77, 78;
vi) 79-81, 82-83, 84;
vii) 85-87, 88-89, 90;
viii) 91-93, 94-95, 96;
ix) 97-99, 100-101, 102;
x) 103-105, 106-107, 108;
xi) 109-111, 112-113, 114;
xi) 115-117, 118-119, 120;
xiii) 121-123, 124-125, 126;
xiv) 127-129, 130-131, 132;
xv) 133-135, 136-137, 138;
xvi) 139-141, 142-143, 144;
xvii) 145-147, 148-149, 150;
xviii) 151-153, 154-155, 156;
xix) 157-159, 160-161, 162;
xx) 163 to 165, 166 to 167, 168;
xxi) 169-171, 172-173, 174;
xxii) 175-177, 178-179, 180;
xxiii) 181 to 183, 184 to 185, 186;
xxiv) 187-189, 190-191, 192;
xxv) 382-384, 385-386, 387;
xxvi) 388-390, 391-392, 393;
xxvii) 394-396, 397-398-399;
xxviii) 400-402, 403-404, 405;
xxix) 406-408, 409-410, 411;
xxx) 412 to 414, 415 to 416, 417;
xxx) 418-420, 421-422, 423;
xxxxi) 424-426, 427-428, 429;
xxxiii) 430-432, 433-434-435;
xxx) 436-438, 439-440, 441;
xxxv) 442-444, 445-446, 447;
xxxvi) 448-450, 451-452, 453;
xxxvii) 454-456, 457-458, 459;
xxxviii) 460-462, 463-464, 465;
xxxix) 466-468, 469-470, 471;
xl) 472-474-475-476, 477;
xli) 478-480, 481-482, 483;
xlii) 484-486, 487-488, 489;
xliii) 490-492, 493-494, 495;
xlive) 496-498, 499-500, 501;
Variable heavy chain domains comprising the amino acid sequences of CDRH1, CDRH2 and CDRH3 selected from one of xlv) 502 to 504, 505 to 506, 507; or xlvi) 508 to 510, 511 to 512, 513; and b) SEQ ID NO: i) 193, 194, 195;
ii) 196, 197, 198;
iii) 199, 200, 201;
iv) 202, 203, 204;
v) 205, 206, 207;
vi) 208, 209, 210;
vii) 211, 212, 213;
viii) 214, 215, 216;
ix) 217, 218, 219;
x) 220, 221, 222;
xi) 223, 224, 225;
xi) 226, 227, 228;
xiii) 229, 230, 231;
xiv) 232, 233, 234;
xv) 235, 236, 237;
xvi) 238, 239, 240;
xvii) 241, 242, 243;
xviii) 244, 245, 246;
xix) 247, 248, 249;
xx) 250, 251, 252;
xxi) 253, 254, 255;
xxii) 256, 257, 258;
xxiii) 259, 260, 261;
xxiv) 262, 263, 264;
xxv) 514, 515, 516;
xxvi) 517, 518, 519;
xxvi) 520, 521, 522;
xxviii) 523, 524, 525;
xxx) 526, 527, 528;
xxx) 529, 530, 531;
xxx) 532, 533, 534;
xxxii) 535, 536, 537;
xxxiii) 538, 538, 540;
xxxiv) 541, 542, 543;
xxxv) 544, 545, 546;
xxxvi) 547, 548, 549;
xxxvii) 550, 551, 552;
xxxviii) 553, 554, 555;
xxxix) 556, 557, 558;
xl) 559, 560, 561;
xli) 562, 563, 564;
xlii) 565, 566, 567;
xliii) 568, 569, 570;
xlive) 571, 572, 573;
56. CD70 specific CAR.
a)49~51、52~53、54、193、194、195;
b)55~57、58~59、60、196、197、198;
c)61~63、64~65、66、199、200、201;
d)67~69、70~71、72、202、203、204;
e)73~75、76~77、78、205、206、207;
f)79~81、82~83、84、208、209、210;
g)85~87、88~89、90、211、212、213;
h)91~93、94~95、96、214、215、216;
i)97~99、100~101、102、217、218、219;
j)103~105、106~107、108、220、221、222;
k)109~111、112~113、114、223、224、225;
l)115~117、118~119、120、226、227、228;
m)121~123、124~125、126、229、230、231;
n)127~129、130~131、132、232、233、234;
o)133~135、136~137、138、235、236、237;
p)139~141、142~143、144、238、239、240;
q)145~147、148~149、150、241、242、243;
r)151~153、154~155、156、244、245、246;
s)157~159、160~161、162、247、248、249;
t)163~165、166~167、168、250、251、252;
u)169~171、172~173、174、253、254、255;
v)175~177、178~179、180、256、257、258;
w)181~183、184~185、186、259、260、261;
x)187~189、190~191、192、262、263、264;
y)382~384、385~386、387、514、515、516;
z)388~390、391~392、393、517、518、519;
aa)394~396、397~398、399、520、521、522;
bb)400~402、403~404、405、523、524、525;
cc)406~408、409~410、411、526、527、528;
dd)412~414、415~416、417、529、530、531;
ee)418~420、421~422、423、532、533、534;
ff)424~426、427~428、429、535、536、537;
gg)430~432、433~434、435、538、539、540;
hh)436~438、439~440、441、541、542、543;
ii)442~444、445~446、447、544、545、546;
jj)448~450、451~452、453、547、548、549;
kk)454~456、457~458、459、550、551、552;
ll)460~462、463~464、465、553、554、555;
mm)466~468、469~470、471、556、557、558;
nn)472~474、475~476、477、559、560、561;
oo)478~480、481~482、483、562、563、564;
pp)484~486、487~488、489、565、566、567;
qq)490~492、493~494、495、568、569、570;
rr)496~498、499~500、501、571、572、573;
ss)502~504、505~506、507、574、575、576;および
tt)508~510、511~512、513、577、578、579、のうちの一つから選択される、CDRH1、CDRH2、CDRH3、CDRL1、CDRL2、およびCDRL3のアミノ酸配列を含むか、または
前記抗原結合分子が、(a)-(tt)のいずれか1つの抗原結合分子とCD70に対する結合に関して競合する、請求項57に記載のCD70特異的CAR。 The antigen-binding molecule is represented by SEQ ID NO: a) 49-51, 52-53, 54, 193, 194, 195;
b) 55-57, 58-59, 60, 196, 197, 198;
c) 61-63, 64-65, 66, 199, 200, 201;
d) 67-69, 70-71, 72, 202, 203, 204;
e) 73-75, 76-77, 78, 205, 206, 207;
f) 79-81, 82-83, 84, 208, 209, 210;
g) 85-87, 88-89, 90, 211, 212, 213;
h) 91-93, 94-95, 96, 214, 215, 216;
i) 97-99, 100-101, 102, 217, 218, 219;
j) 103-105, 106-107, 108, 220, 221 222;
k) 109-111, 112-113, 114, 223, 224, 225;
l) 115-117, 118-119, 120, 226, 227, 228;
m) 121-123, 124-125, 126, 229, 230, 231;
n) 127-129, 130-131, 132, 232, 233, 234;
o) 133-135, 136-137, 138, 235, 236, 237;
p) 139-141, 142-143, 144, 238, 239, 240;
q) 145 to 147, 148 to 149, 150, 241 and 242, 243;
r) 151-153, 154-155, 156, 244, 245, 246;
s) 157-159, 160-161, 162, 247, 248, 249;
t) 163 to 165, 166 to 167, 168, 250, 251, 252;
u) 169-171, 172-173, 174, 253, 254, 255;
v) 175-177, 178-179, 180, 256, 257, 258;
w) 181 to 183, 184 to 185, 186, 259, 260, 261;
x) 187-189, 190-191, 192, 262, 263, 264;
y) 382-384, 385-386, 387, 514, 515, 516;
z) 388-390, 391-392, 393, 517, 518, 519;
aa) 394-396, 397-398, 399, 520, 521, 522;
bb) 400-402, 403-404, 405, 523, 524, 525;
cc) 406-408, 409-410, 411, 526, 527, 528;
dd) 412 to 414, 415 to 416, 417, 529, 530, 531;
ee) 418-420, 421-422, 423, 532, 533, 534;
ff) 424-426, 427-428, 249, 535, 536, 537;
gg) 430-432, 433-434, 435, 538, 538, 540;
hh) 436-438, 439-440, 441, 541, 542, 543;
ii) 442-444, 445-446, 447, 544, 545, 546;
jj) 448-450, 451-452, 453, 547, 548, 549;
kk) 454-456, 457-458, 459, 550, 551, 552;
ll) 460-462, 463-464, 465, 555, 554, 555;
mm) 466-468, 469-470, 471, 556, 557, 558;
nn) 472-474, 475-476, 477-559, 560, 561;
oo) 478-480, 481-482, 483, 562, 563, 564;
pp) 484-486, 487-488, 489, 565, 566, 567;
qq) 490-492, 493-494, 495, 568, 569, 570;
rr) 496-498, 499-500, 501, 571, 572, 573;
ss) 502 to 504, 505 to 506, 507, 574, 575, 576; and tt) 508 to 510, 511 to 512, 513, 777, 578, 579, selected from CDRH1, CDRH2. , Contains the amino acid sequences of CDRH3, CDRL1, CDRL2, and CDRL3 , or
22. The CD70-specific CAR of claim 57, wherein the antigen-binding molecule competes for binding to CD70 with any one of (a)-(tt) antigen-binding molecules .
a)それぞれ、配列番号1、3、5、7、9、11、13、15、17、19、21、23、25、27、29、31、33、35、37、39、41、43、45、47、338、340、342、344、346、348、350、352、354、356、358、360、362、364、366、368、370、372、374、376、378、および380のうちの一つから選択されるCDRH1、CDRH2、およびCDRH3のアミノ酸配列を含む可変軽鎖ドメイン、および
b)それぞれ、配列番号2、4、6、8、10、12、14、16、18、20、22、24、26、28、30、32、34、36、38、40、42、44、46、48、339、341、343、345、347、349、351、353、355、357、359、361、363、365、367、369、371、373、375、377、379、および381のうちの一つから選択されるCDRL1、CDRL2、およびCDRH3のアミノ酸配列を含む可変重鎖ドメイン、を含む、請求項56に記載のCD70特異的CAR。 The antigen-binding molecule
a) SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, respectively. Of 45, 47, 338, 340, 342, 344, 346, 348, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 378, and 380. A variable light chain domain comprising the amino acid sequences of CDRH1, CDRH2, and CDRH3 selected from one of b) SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, respectively, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 339, 341, 343, 345, 347, 349, 351, 353, 355, 357, 359, Includes a variable heavy chain domain comprising the amino acid sequences of CDRL1, CDRL2, and CDRH3 selected from one of 361, 363, 365, 376, 369, 371, 373, 375, 377, 379, and 381. The CD70-specific CAR according to claim 56.
a)1および2;
b)3および4;
c)5および6;
d)7および8;
e)9および10;
f)11および12;
g)13および14;
h)15および16;
i)17および18;
j)19および20;
k)21および22;
l)23および24;
m)25および26;
n)27および28;
o)29および30;
p)31および32;
q)33および34;
r)35および36;
s)37および38;
t)39および40;
u)41および42;
v)43および44;
w)45および46;
x)47および48;
y)338および339;
z)340および341;
aa)342および343;
bb)344および345;
cc)346および347;
dd)348および349;
ee)350および351;
ff)352および353;
gg)354および355;
hh)356および357;
ii)358および359;
jj)360および361;
kk)362および363;
ll)364および365;
mm)366および367;
nn)368および369;
oo)370および371;
pp)372および373;
qq)374および375;
rr)376および377;
ss)378および379;および
tt)380および381、のうちの一つから選択される軽鎖可変ドメインおよび重鎖可変ドメインのアミノ酸配列を含むか、または
前記抗原結合分子が、(a)-(tt)のいずれか1つの抗原結合分子とCD70に対する結合に関して競合する、請求項59に記載のCD70特異的CAR。 The antigen-binding molecule is SEQ ID NO: a) 1 and 2, respectively;
b) 3 and 4;
c) 5 and 6;
d) 7 and 8;
e) 9 and 10;
f) 11 and 12;
g) 13 and 14;
h) 15 and 16;
i) 17 and 18;
j) 19 and 20;
k) 21 and 22;
l) 23 and 24;
m) 25 and 26;
n) 27 and 28;
o) 29 and 30;
p) 31 and 32;
q) 33 and 34;
r) 35 and 36;
s) 37 and 38;
t) 39 and 40;
u) 41 and 42;
v) 43 and 44;
w) 45 and 46;
x) 47 and 48;
y) 338 and 339;
z) 340 and 341;
aa) 342 and 343;
bb) 344 and 345;
cc) 346 and 347;
dd) 348 and 349;
ee) 350 and 351;
ff) 352 and 353;
gg) 354 and 355;
hh) 356 and 357;
ii) 358 and 359;
jj) 360 and 361;
kk) 362 and 363;
ll) 364 and 365;
mm) 366 and 367;
nn) 368 and 369;
oo) 370 and 371;
pp) 372 and 373;
qq) 374 and 375;
rr) 376 and 377;
Contains or contains amino acid sequences of light chain variable domains and heavy chain variable domains selected from one of ss) 378 and 379; and tt) 380 and 381.
The CD70-specific CAR according to claim 59, wherein the antigen-binding molecule competes with any one of (a)-(tt) for binding to CD70 .
a)前記細胞群は、幹細胞メモリー細胞およびセントラルメモリー細胞の20%、30%または40%よりも高い割合を構成し、および/または
b)前記細胞群は、実施例4に開示されるアッセイを使用して測定されるときに、6日目で、再帰的CD70発現細胞に対し、10%、20%、30%または40%よりも高いCD70発現細胞の溶解割合を達成する、細胞群。 The group of cells according to any one of claims 76 to 87.
a) The cell population constitutes a proportion greater than 20%, 30% or 40% of stem cell memory cells and central memory cells, and / or b) the cell population comprises the assay disclosed in Example 4. A group of cells that achieves a lysis rate of CD70-expressing cells greater than 10%, 20%, 30% or 40% relative to recursive CD70-expressing cells when measured using.
a)免疫細胞を提供すること、および
b)前記細胞に、請求項56~73のいずれか1項に記載の前記CD70特異的CARをコードする少なくとも一つのポリヌクレオチドを導入すること、を含む、方法。 A method of manipulating immune cells
It comprises providing immune cells and b) introducing at least one polynucleotide encoding the CD70-specific CAR according to any one of claims 56-73 into the cells. Method.
a)請求項56~73のいずれか1項に記載のCD70特異的CARを、表面に発現する免疫細胞を提供すること、および
b)前記免疫細胞を前記患者に投与すること、を含む、方法。 It ’s a way to treat the subject in need,
A method comprising a) providing an immune cell expressing the CD70-specific CAR according to any one of claims 56 to 73 on the surface, and b) administering the immune cell to the patient. ..
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023176445A JP2024016034A (en) | 2018-02-01 | 2023-10-12 | Chimeric antigen receptor targeting CD70 |
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862625009P | 2018-02-01 | 2018-02-01 | |
US201862625019P | 2018-02-01 | 2018-02-01 | |
US62/625,009 | 2018-02-01 | ||
US62/625,019 | 2018-02-01 | ||
US201862641873P | 2018-03-12 | 2018-03-12 | |
US201862641869P | 2018-03-12 | 2018-03-12 | |
US62/641,869 | 2018-03-12 | ||
US62/641,873 | 2018-03-12 | ||
US201862775246P | 2018-12-04 | 2018-12-04 | |
US62/775,246 | 2018-12-04 | ||
PCT/US2019/016189 WO2019152742A1 (en) | 2018-02-01 | 2019-01-31 | Chimeric antigen receptors targeting cd70 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023176445A Division JP2024016034A (en) | 2018-02-01 | 2023-10-12 | Chimeric antigen receptor targeting CD70 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021511807A JP2021511807A (en) | 2021-05-13 |
JPWO2019152742A5 true JPWO2019152742A5 (en) | 2022-02-04 |
JP7404247B2 JP7404247B2 (en) | 2023-12-25 |
Family
ID=65686921
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020541882A Active JP7404247B2 (en) | 2018-02-01 | 2019-01-31 | Chimeric antigen receptor targeting CD70 |
JP2023176445A Pending JP2024016034A (en) | 2018-02-01 | 2023-10-12 | Chimeric antigen receptor targeting CD70 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023176445A Pending JP2024016034A (en) | 2018-02-01 | 2023-10-12 | Chimeric antigen receptor targeting CD70 |
Country Status (15)
Country | Link |
---|---|
US (2) | US11396551B2 (en) |
EP (1) | EP3746483A1 (en) |
JP (2) | JP7404247B2 (en) |
KR (1) | KR20200128018A (en) |
CN (1) | CN112020518A (en) |
AU (1) | AU2019216420A1 (en) |
BR (1) | BR112020015662A2 (en) |
CA (1) | CA3089318A1 (en) |
IL (1) | IL276396A (en) |
MX (1) | MX2020008184A (en) |
PE (1) | PE20211299A1 (en) |
PH (1) | PH12020551160A1 (en) |
SG (1) | SG11202006883QA (en) |
TW (1) | TW201936633A (en) |
WO (1) | WO2019152742A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3298033T5 (en) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Compositions and medical uses for tcr reprogramming using fusion proteins |
BR112020015641A2 (en) | 2018-02-01 | 2021-01-05 | Pfizer Inc. | SPECIFIC ANTIBODIES FOR CD70 AND ITS USES |
EP3790629A1 (en) | 2018-05-11 | 2021-03-17 | CRISPR Therapeutics AG | Methods and compositions for treating cancer |
CN109053882B (en) * | 2018-08-28 | 2019-08-23 | 东莞市朋志生物科技有限公司 | A kind of binding protein of NS1 albumen and application |
BR112022003891A2 (en) * | 2019-09-06 | 2022-05-31 | Crispr Therapeutics Ag | Genetically engineered t cells having improved persistence in culture |
US20220411478A1 (en) * | 2019-09-16 | 2022-12-29 | The General Hospital Corporation | Cd70 targeted chimeric antigen receptor (car) t cells and uses thereof |
US20220387571A1 (en) * | 2019-11-13 | 2022-12-08 | Crispr Therapeutics Ag | Therapy for hematopoietic cell malignancies using genetically engineered t cells targeting cd70 |
JP2023501611A (en) * | 2019-11-13 | 2023-01-18 | クリスパー セラピューティクス アクチェンゲゼルシャフト | CD70+ Solid Tumor Therapy Using Genetically Engineered T Cells Targeting CD70 |
BR112022009204A2 (en) * | 2019-11-13 | 2022-07-26 | Crispr Therapeutics Ag | RENAL CELL CARCINOMA (RCC) THERAPY USING GENETICALLY MANIPULATED T CELLS TARGETING CD70 |
JP2023501617A (en) * | 2019-11-13 | 2023-01-18 | クリスパー セラピューティクス アクチェンゲゼルシャフト | Method for producing CAR-T cells |
CN115397853A (en) * | 2019-12-17 | 2022-11-25 | 辉瑞大药厂 | Antibody with specificity to CD47 and PD-L1 and application thereof |
JP2023524811A (en) * | 2020-05-05 | 2023-06-13 | ティーシーアール2 セラピューティクス インク. | Compositions and methods for TCR reprogramming using CD70-specific fusion proteins |
WO2022076788A1 (en) * | 2020-10-09 | 2022-04-14 | Memorial Sloan Kettering Cancer Center | Compositions targeting ndc80/mhc complexes and uses thereof |
WO2022104109A1 (en) | 2020-11-13 | 2022-05-19 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
US20220162288A1 (en) | 2020-11-25 | 2022-05-26 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
US20220227832A1 (en) | 2020-12-21 | 2022-07-21 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
MX2023008809A (en) | 2021-01-29 | 2023-08-04 | Allogene Therapeutics Inc | KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, ß2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS. |
TW202310870A (en) * | 2021-05-12 | 2023-03-16 | 瑞士商Crispr治療公司 | Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies |
AR125852A1 (en) * | 2021-05-12 | 2023-08-16 | Crispr Therapeutics Ag | GENETICALLY MODIFIED IMMUNE CELLS THAT FOCUS ON CD70 FOR USE IN THE TREATMENT OF SOLID TUMORS |
AU2022292640A1 (en) | 2021-06-15 | 2023-11-30 | Allogene Therapeutics, Inc. | Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence |
WO2023278520A1 (en) * | 2021-06-30 | 2023-01-05 | Board Of Regents, The University Of Texas System | Polypeptides targeting cd70-positive cancers |
WO2023072307A1 (en) * | 2021-10-25 | 2023-05-04 | 重庆精准生物技术有限公司 | Antigen binding fragment targeting cd70, single-chain antibody and chimeric antigen receptor, and use thereof |
US20240042030A1 (en) | 2022-07-29 | 2024-02-08 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
WO1995013796A1 (en) | 1993-11-16 | 1995-05-26 | Depotech Corporation | Vesicles with controlled release of actives |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0832980B1 (en) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
WO1990011092A1 (en) | 1989-03-21 | 1990-10-04 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
WO1991002805A2 (en) | 1989-08-18 | 1991-03-07 | Viagene, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2108048T3 (en) | 1990-08-29 | 1997-12-16 | Genpharm Int | PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES. |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
JPH06507398A (en) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Heterogeneous conjugate antibody for treatment of HIV infection |
DE69233482T2 (en) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JP4124480B2 (en) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
WO1993003769A1 (en) | 1991-08-20 | 1993-03-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
DK0605522T3 (en) | 1991-09-23 | 2000-01-17 | Medical Res Council | Process for producing humanized antibodies |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
FR2688514A1 (en) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1993025234A1 (en) | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
JPH09507741A (en) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | Vector particles resistant to inactivation by human serum |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
PT695169E (en) | 1993-04-22 | 2003-04-30 | Skyepharma Inc | MULTI-SCIENTIFIC LIPOSOMES OF CYCLODEXTRIN ENCAPSULATING PHARMACOLOGICAL COMPOUNDS AND METHODS FOR THEIR UTILIZATION |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
JP3532566B2 (en) | 1993-06-24 | 2004-05-31 | エル. グラハム,フランク | Adenovirus vectors for gene therapy |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
DE69435233D1 (en) | 1993-09-15 | 2009-10-08 | Novartis Vaccines & Diagnostic | Recombinant alphavirus vectors |
ATE437232T1 (en) | 1993-10-25 | 2009-08-15 | Canji Inc | RECOMBINANT ADENOVIRUS VECTOR AND METHOD OF USE |
US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
ATE381624T1 (en) | 1994-05-09 | 2008-01-15 | Oxford Biomedica Ltd | RETROVIRAL VECTORS WITH REDUCED RECOMBINATION RATE |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
DE69739286D1 (en) | 1996-05-06 | 2009-04-16 | Oxford Biomedica Ltd | RECOMBINATION-INCOMPATIBLE RETROVIRAL VECTORS |
US6376471B1 (en) | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
JP2004500095A (en) | 2000-02-24 | 2004-01-08 | エクサイト セラピーズ, インコーポレイテッド | Simultaneous stimulation and enrichment of cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
NZ540730A (en) | 2002-12-24 | 2010-09-30 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods using same |
EP1799262A4 (en) | 2004-10-15 | 2009-10-21 | Seattle Genetics Inc | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders |
AU2006236508B2 (en) | 2005-04-15 | 2012-02-02 | Precision Biologics, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
AU2006236225C1 (en) | 2005-04-19 | 2013-05-02 | Seagen Inc. | Humanized anti-CD70 binding agents and uses thereof |
ES2527961T3 (en) | 2005-09-26 | 2015-02-02 | Medarex, L.L.C. | Human monoclonal antibodies to CD70 |
JPWO2010024300A1 (en) | 2008-08-26 | 2012-01-26 | 国立大学法人北海道大学 | Bone filling type cartilage tissue regeneration inducer |
WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
US20130337454A1 (en) | 2010-10-27 | 2013-12-19 | Philippe Duchateau | Method for increasing the efficiency of double-strand break-induced mutagenesis |
KR20140002649A (en) | 2010-10-27 | 2014-01-08 | 베이롤 칼리지 오브 메드신 | Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies |
EP2635310A2 (en) | 2010-11-05 | 2013-09-11 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
PT2686347T (en) | 2011-03-16 | 2018-07-05 | Argenx Bvba | Antibodies to cd70 |
GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
CN104769103B (en) | 2012-09-04 | 2018-06-08 | 塞勒克提斯公司 | Multichain Chimeric antigen receptor and its purposes |
WO2014184744A1 (en) | 2013-05-13 | 2014-11-20 | Cellectis | Methods for engineering highly active t cell for immunotherapy |
FI3546572T3 (en) | 2013-05-13 | 2024-05-06 | Cellectis | Cd19 specific chimeric antigen receptor and uses thereof |
US9890393B2 (en) | 2013-05-29 | 2018-02-13 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system |
JP6521959B2 (en) | 2013-07-31 | 2019-05-29 | ライナット ニューロサイエンス コーポレイション | Engineered polypeptide conjugates |
US10836998B2 (en) | 2014-02-14 | 2020-11-17 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
JP6724009B2 (en) * | 2014-12-08 | 2020-07-15 | アメリカ合衆国 | Anti-CD70 chimeric antigen receptor |
BR112017015453A2 (en) | 2015-01-26 | 2018-01-23 | Cellectis | CD123-linked chimeric t-cell receptor knockout modified immune cells for the treatment of recurrent / refractory acute myeloid lymphoma or blastic neoplasia of plasmacitoid dendritic cells |
DE102015101304B3 (en) | 2015-01-29 | 2016-03-17 | Fujitsu Technology Solutions Intellectual Property Gmbh | Rack server for a server rack |
WO2016166630A1 (en) | 2015-04-13 | 2016-10-20 | Pfizer Inc. | Chimeric antigen receptors targeting b-cell maturation antigen |
KR102405104B1 (en) | 2015-04-13 | 2022-06-07 | 화이자 인코포레이티드 | Therapeutic antibodies and their uses |
TWI717375B (en) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for cd70 and cd3 |
US10221242B2 (en) | 2016-01-21 | 2019-03-05 | Pfizer Inc. | Antibodies specific for epidermal growth factor receptor variant III and their uses |
EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
WO2018152181A1 (en) | 2017-02-14 | 2018-08-23 | Kite Pharma, Inc. | Cd70 binding molecules and methods of use thereof |
BR112020015641A2 (en) | 2018-02-01 | 2021-01-05 | Pfizer Inc. | SPECIFIC ANTIBODIES FOR CD70 AND ITS USES |
-
2019
- 2019-01-31 TW TW108103959A patent/TW201936633A/en unknown
- 2019-01-31 BR BR112020015662-0A patent/BR112020015662A2/en unknown
- 2019-01-31 SG SG11202006883QA patent/SG11202006883QA/en unknown
- 2019-01-31 JP JP2020541882A patent/JP7404247B2/en active Active
- 2019-01-31 AU AU2019216420A patent/AU2019216420A1/en active Pending
- 2019-01-31 WO PCT/US2019/016189 patent/WO2019152742A1/en unknown
- 2019-01-31 CA CA3089318A patent/CA3089318A1/en active Pending
- 2019-01-31 KR KR1020207025214A patent/KR20200128018A/en not_active Application Discontinuation
- 2019-01-31 US US16/264,371 patent/US11396551B2/en active Active
- 2019-01-31 PE PE2020001165A patent/PE20211299A1/en unknown
- 2019-01-31 EP EP19709580.5A patent/EP3746483A1/en active Pending
- 2019-01-31 MX MX2020008184A patent/MX2020008184A/en unknown
- 2019-01-31 CN CN201980024740.XA patent/CN112020518A/en active Pending
-
2020
- 2020-07-29 IL IL276396A patent/IL276396A/en unknown
- 2020-07-30 PH PH12020551160A patent/PH12020551160A1/en unknown
-
2022
- 2022-06-17 US US17/843,616 patent/US20230041456A1/en active Pending
-
2023
- 2023-10-12 JP JP2023176445A patent/JP2024016034A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2019152742A5 (en) | ||
TWI786188B (en) | Novel Bispecific Peptide Complex | |
CN103502274B (en) | Anti-IL-6 receptor antibody and using method thereof | |
JP7041516B2 (en) | Bispecific antibodies or antibody mixtures with common light chains | |
CN103068846B (en) | Comprise the bi-specific antibody of disulfide bond stability Fv fragment | |
CN117024593A (en) | anti-SIRP alpha antibodies | |
CN104918957A (en) | Anti-CD40 antibodies and methods of use | |
CA3096123A1 (en) | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses | |
JP2018519364A5 (en) | ||
JP2021525080A5 (en) | ||
DE60033455T2 (en) | Human monoclonal antibody to Ep-CAM and its use in cancer therapy | |
CA3091764A1 (en) | Antibody variable domains targeting cd33, and use thereof | |
CN103635488A (en) | Anti-CD40 antibodies and methods of use | |
CA3091424A1 (en) | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use | |
CN113195530B (en) | Antibody fusion protein, preparation method and application thereof | |
IL292780A (en) | New 4-1bbl trimer-containing antigen binding molecules | |
CA3111462A1 (en) | Improved anti-flt3 antigen binding proteins | |
CN105189551A (en) | Anti-RANKL antibodies and methods of use | |
WO2008152537A2 (en) | Humanized monoclonal antibodies against human epidermal growth factor receptor, use and method thereof | |
RU2020128741A (en) | Chimeric antigen receptors targeting CD70 | |
EP4253416A1 (en) | Anti-sirpalpha antibody or antigen-binding fragment thereof, and use thereof | |
WO2021241730A1 (en) | Therapeutic antibody for inflammatory bowel disease | |
WO2023199927A1 (en) | Use of anti-tspan8-anti-cd3 bispecific antibody combined with pd-1 signal inhibitor for cancer treatment | |
US20220204613A1 (en) | Anti-cd47 antibodies and uses thereof | |
WO2024061352A1 (en) | Isolated antigen-binding protein and use thereof |